Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma
Status:
Recruiting
Trial end date:
2024-07-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find the highest dose of a new drug, in combination with
standard drugs, which can be tolerated without causing very severe side effects. The study
treatment is new agents in combination with R-GDP or an equivalent regimen.